The Bultavo-3 vaccine for bluetongue virus serotype 3 (BTV-3) is expected to require annual administration for sheep and cattle, according to Dr. Ruth Sanders, superintending veterinary inspector with the Department of Agriculture. While current product labels from the Health Products Regulatory Authority (HPRA) and the UK’s Veterinary Medicines Directorate list the duration of immunity as not established, manufacturers are seeking full-year efficacy status.
Why is annual vaccination likely for BTV-3?
Manufacturers, including Boehringer Ingelheim, have submitted data to regulatory authorities aiming to confirm a full 12-month duration of immunity. Dr. Sanders, speaking at the Teagasc National Sheep Conference, noted that once this data is fully processed, the vaccine will likely follow an annual schedule similar to other established livestock immunizations. Currently, three vaccines approved for use in Ireland and the UK—Bultavo-3, Bluevac-3, and Syvazul BTV 3—all carry an “immunity not established” status on their official product characteristics.
How does vaccination impact bluetongue symptoms?
Vaccination serves as the primary tool for mitigating the risk of clinical disease and mortality in livestock. According to Dr. Sanders, the vaccine works by reducing viraemia—the presence of the virus in the bloodstream—and limiting the severity of clinical signs. While mortality rates in the continental EU have been high, cases in Ireland and parts of the UK have presented differently. Notably, farmers in England and Wales are reporting significant fertility issues in infected herds, even in the absence of severe clinical symptoms seen elsewhere.
Comparing vaccine protocols for livestock
There are distinct differences in how species must be treated to achieve immunity against BTV-3. The following table breaks down the current application requirements based on manufacturer guidelines:
| Species | Dosing Schedule |
|---|---|
| Sheep | Single dose, immunity built after three weeks |
| Cattle | Initial dose, followed by a booster three weeks later |
Frequently Asked Questions
- Is the Bultavo-3 vaccine considered a permanent cure? No, it is an active immunization to reduce viraemia and prevent mortality; it requires periodic boosters.
- Why is the duration of immunity “not established” on the label? This is a standard regulatory status for new vaccines until long-term field data is finalized and approved by authorities like the HPRA.
- Should I vaccinate my herd if I haven’t seen symptoms? Dr. Sanders advises farmers to consider vaccination, as it is impossible to predict the prevalence or severity of the virus in future seasons.
Are you managing your herd’s vaccination strategy for the coming year? Share your experiences with BTV-3 protocols in the comments below or subscribe to our newsletter for the latest updates on veterinary health regulations.
